219 Results

Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.

Background: Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenström's macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to rituximab...

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

We compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma.

Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects.

Mantle cell lymphoma (MCL) is a lymphoproliferative disorder comprising about 6-10% of all B cell lymphoma cases. Ibrutinib is an inhibitor of Bruton tyrosine kinase (BTK), a key component of early B-cell receptor (BCR) signalling pathways.

Systematic review of infectious events with the BTK inhibitor ibrutinib in the treatment of haematologic malignancies.

Objective: Ibrutinib is an irreversible inhibitor of Bruton tyrosine kinase (BTK) in B-lymphocytes as well as other kinases including interleukin-2-inducible T-cell kinase (ITK) in CD4+ Th2 regulatory T-cells.

Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma.

Background: B-cell survival is regulated through interactions of B-cell-activating factor and a proliferation-inducing ligand with their receptors transmembrane activator and CAML interactor (TACI) and B-cell maturation antigen...

Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.

Introduction: A combination of granulocyte colony-stimulating factor (G-CSF) and chemotherapy or G-CSF alone are the most common mobilization regimens for autotransplantations.

Plerixafor for stem cell mobilization: the current status.

Purpose of review: Nowadays, plerixafor is approved for patients who fail to mobilize sufficient CD34⁺ cells for an autologous stem cell transplantation. Plerixafor is effective in the majority of these patients...

Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.

Background: The combination of rituximab with chemotherapy has improved the outcome of patients with follicular lymphoma (FL). However, data on Grade 3 FL (FL3) and its subtypes are lacking.

Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.

Brentuximab vedotin is an antibody-drug conjugate that brings the antimicrotubule agent monomethyl auristatin E into CD30-expressing cells. Some prior studies could demonstrate good efficacy in cutaneous lymphomas.

Load more